c1uding CEOP a nd KSS (8) (9) (10) (11) (12) (13) (14) , and MERRF associated with stroke-like symptoms ( 15) .
Each human cell has thousands of mtDNA (16) , each coding for a complete set of ribosom al RNA and transfer RNA, as well as 13 polypeptides of oxidative phosphorylation. Th ese polypeptides includ e seven subunits (ND I, 2, 3, 4, 4L, 5, and 6) of respiratory compl ex I (NADH-ubiquinol oxidoreductase), one subunit (cyt b) of respirato ry complex III (ubiquinol-cytochrome c oxidoreductase), three subunits (Ca l, Ca ll , and COIll) of compl ex IV (cytochrome c oxidase), and two subunits (AT P6 and 8) of complex V (AT P synthase).
The genetics of the human mtDNA abide by three uni que principles. First, the y are mat ernally inherited (17, 18) . Second , mixed populations of mutant and wild-type mtDNA (heteroplasmy) segregate du ring cellular replication toward pure populations (homoplasmy) (19) . When th e mutation is a large deletion, the deleted molecules become enrich ed over time becaus e replication rate is proportional to the length of the molecule and the smaller molecules replicate faster (3) . Th ird, a cell will express a mtDNA mutant phenotype only when the extent of cellular energy deprivation falls below the minimum level required by that cell for normal function (2, 19) .
Unti l recently, the diagnosis of the mitochond rial enceph alomyopathies has relied on clinical, histochem ical, and biochemical anal ysis (5, 20) . However, the identification of molecular defects in these patient s now makes molecular diagnosis feasible. Th e PCR technique (2 1) has made these tests preferable to more conventional appr oaches because it permits a molecular diagnosis from very limited specimen material. In this report, we will summarize current knowledge about mtDNA mutations associated with neuromuscular diseases and describe how the PCR perm its rapid and accurate diagnosis of these compl ex diseases.
mtD NA ex traction and Pt.R, mtDNA was enri ched from fresh or frozen muscle as previou sly described (5) . PCR was used to amplify normal and deleted mtDNA using synthetic oligonucleotides as primers (Microchemical Facility, Emory Un iversity). T he IaO-JLL PCR reactions contained 200 JLM of each dNTP (dATP , dTTP, dCTP , and dGTP), 50 mM KCI, 10 mM Tri s-C1, pH 8.3, 1.5 mM MgCh, 0.0 1% (wt/v ol gelatin), 30 pmol of each prim er, and 2.5 U Taq polymerase (Perkins Elmer Cetus, Norwalk, CT). No oil overlay was used. When multiple primer pairs are included in a single reaction, 30 pmol of each forward and reverse primer per target were used. peR-generated DNA was visualized on agarose gels with ethidium brom ide.
Sequencing. Asymmetrically PCR-amplified DNA for dideoxy sequencing was prepared by adding one prim er in laO-fold excess 525 Abbreviations mtDNA, mitochondrial DNA PCR, polymerase chain reaction RRF, ragged red fiber MERRF, myoclonic epilepsy and ragged red fiber disease MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms KSS, Kearns-Sayre syndrome CEOP, chronic external ophthalmoplegia plus nt, nucleotide LHON, Leber's hereditary optic neuropathy 011, heavy strand origin OL, light strand origin ABSTRACT. A number of neuromuscular diseases are associated with molecular defects in the mitochondrial DNA (mtDNA). These include: 1) a missense mutation at nucleotide 11778 in the mtDNA of Leber's hereditary optic neuropathy patients; 2) a heterogeneous array of deletions in the mtDNA of ocular myopathy patients; and 3) small deletions and point mutations in the mtDNA of myoclonic epilepsy and ragged red fiber disease patients. We can now diagnose these diseases at the molecular level from small patient samples by amplifying the affected mtDNA regions using the polymerase chain reaction. Leber's hereditary optic neuropathy is diagnosed through loss of an SfaNI restriction site. Ocular myopathy deletions are identified by differential amplification across deletion breakpoints. Familial diseases such as myoclonic epileps y and ragged red fiber disease might be diagnosed by identifying small deletions through amplification and electrophoretic analysis of the entire mtDNA genome or by identifying point mutations through differential oligonucleotide hybridization. As additional mtDNA molecular defects are identified, molecular analysis will likely become a primary tool for the diagnosis of these diseases. The forward (... ) primer was located at nt7392-7410 and reverse (... ) primers were located at nt92 44-9225 and nt 13950-13932 of the published human mtD NA sequence (27) . Th e nt73 92(-» and nt9244H prim er pair amplified a l85 2-bp fragment from wild-type DNA templ ate. Th e nt7392(-» and ntl 3950H primer pair ampl ified a l581-bp fragment from the deleted mtDNA. L ower panel: PCR am plification products of muscle mtDNA, visualized with ethidium bromid e. P, proband ; Sf and S2, sisters of the proba nd; Std, mo l wt standards. The 1852-bp fragmen t is seen in all samp les, whereas the 1581-bp fragmen t is only seen in the patient with the deletion (23). We have found that deletions in the two-third s arc are associated with a 13-bp direct repeat (ACCTCCCTCACCA) at nt8470 -8482 and ntI 3447-13459. This results in a 4977-bp deletion remo ving parts of AT Pase 8 and ND5 and all of the inte rvenin g genes including AT Pase 6, com, ND 3, ND4L, and ND4 . Numerous other direct repeats located in the two-th irds arc could account for most of the remaining mtDNA deletions through a slip replication (23) or homologous recombination (29) .
Because these deletions appear as clonal, spontaneous mutation s during somatic developm ent , molecular analysis must be don e on the affected tissue. For the ocular myopathies, this requir es a muscle specimen, which can be reduced to a needle biopsy when using peR. mtDNA deletions associated with other tissues, such as pan cytopen ia (30, 31) , require the sample from the appropriate tissue.
Approximately 40% of mtDNA deletions are associated with the 13-bp repeat ( 14, 29) . Therefore, man y optic myopath y patient s can be diagnosed at the molecular level using PCR primers specific for th is deletion. We can simultaneously ampl ify both the norm al and deleted mtDNA using a forward primer at nt73 92{-» and two reverse primers at nt9244(<' -) and nt1 3950H .
bp 117 bp
95 bp of the other (22) . The thermal amplification profile, sequencing reaction mixtures, and PAGE protocols have been previously described (23) . The procedure has been further modified by substituting 7-deaza-2' -deoxyguanosine-5' -triph osph ate for deoxyguanosine-5'-tripho sphate in all nucleotide mixes to eliminate the G-C compression commo n in mtDNA sequen ces. Fig. 1 . Th e 212-bp PCR-gener ated mtDNA fragment from LHO N patients (P) and normal con trols (C) digested with SfaN! and visualized with ethidi um bromide on a 2.5% NuSieve, 0.9% Sea Kern agarose gel.
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RESULTS
LHON: PCR diagnosis of a specific base change. LHON is a maternall y inherited disease (24) associated with late onset bilateral optic nerve death . During the acute phase, the opti c nerve dies from the center outward, leading to central retin al scotoma . Before the acute phase, retinal examination reveals tortuous vessels and microan giopathy. Cardiac dysrhythm ia is also a common finding, but muscle pathology has not been observed (2, 25, 26) .
We have identified the mtDNA mutation responsible for most cases of LHON. This mutation changes ntll 778 (27) from an A to a G and converts the 340th amino acid of NADH dehydrogenase from an arginine to a histidin e. The mutation has been found in 80% of patient s diagnosed with LHON, but is not found in the general popul ation (6) . Analysis of mtD NA haplot ypes from America n black and European white LHON patients has revealed that the mutation has occurred at least twice and in both cases resulted in the disease (7). The NADH dehydrogenase deficiency has been confirmed biochemicall y in one family (28) . Thus, this mutatio n is a cause of the symptoms.
Th e LHON nucleotide substitution eliminates a SfaN! restriction site in th e patient' s mtD NA, providing a molecular diagnostic test for this disease. The sequence surro unding the mut ation is amplified from blood cell DNA using primers at ntI1673(...) and 11 875(<, -) to yield a 2 12-bp fragment. Digestion of this fragment with SfaN! cut s the fragment into 117-bp and 95-bp fragments in control individuals but does not cut the fragment in patients with the mutation. Th e digestion products are readily resolved on NuSieve (FM C Bio Products, Rockland , ME) agarose gels and detected by staining with ethidium bromide (Fig. I ) (6) .
Ocular myopat hies and other deletion syndromes: PCR diagnosis of deletions. The ocular myopathies are associated with chronic external ophthalmoplegia, ptosis, and RRF. More severe cases can also include neuros ensory hearing loss, cerebellar ataxia, elevated cerebrospinal fluid lactate and protein, and cardiac dysrhythmi as. Th e mild cases are described as CEOP, and the more severe are designated KSS (2, 20) . mtDNA deletions associated with CEOP and KSS have been mapped to two sectors of the genome. Most deletion s are located within the two-thirds of the genome encompassed by the OH and Fig. 4 . Dideoxy sequencing using PCR-generated single-stranded mtDNA. The PCR amplification used primers at nt 12861 and nt13950 in a ratio of 100: I. The boxed nucleo tide reveals the deviation from the published sequence at nt 13702.
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MtDNA MUTATIONS AND NEUROMUSCULAR DISEASE
Primers at nt7392H and nt9244(<-) amplify a I.9 -kb fragmen t from the normal m tDNA and primers nt7392H and nt 13950«-) am plify at 1.6-kb fragme nt from the deleted mtDNA. The former acts as an intern al control for the latt er; the diagnosis is made if both fragments are observed on an eth idium bromide-stained agarose gel (23) (Fig. 2) . Add itio nal deletion s in the two-th irds OWtO-OL arc cou ld be defined by combining several forward primers and/or reverse primers (32) .
MERRF: peR screening for intragenic deletions and point mutations. ME RRF is a maternally inherited encephalomyopath y associa ted with uncontrolled m yoclonu s epilepsy and RRF (5, 20) . We have cha racterized a large pedigree associated with ME RRF and demonstrated that this pedigree has all of the characteristics expected for a heteroplasmic mtDNA mutation. First, the disease is maternally inherited with every individual alo ng the ma ternal lin eage being affected to some degree. Second, the severity of the sym pt oms along th e matern al lineage varies from an individual with severe disease manifestations including m yoclonus, dementia, hypoventilation, hearing loss, RR F, and severe electrophysiologic abnormalities of the CNS to an individual with onl y mild manifestations in the visual evoked response and EEG . T hird, individuals along the maternal lineage have a biochemical defect in complexes I and IV of m uscle and the severity of an individual's biochemical defect is directly proportio na l to th e severity of his clinical manifestations (5) .
Although MERRF patients ha ve RRF, they are not associated with large deletions (5, 14) . Howe ver, one patient with MERRF, who also displays the stroke-like symptoms of MELAS, had a OA-kb deletion in the ND5 gene (15) . Therefore, at least some MERRF and MELAS cases appear to result from mtDNA point m utations or small intragenic deletions.
To distinguish between these cases, we have prepared a series of p e R primers permitting amplification of all human m tDNA coding regions in nine fragmen ts. The mt DNA fragments of the pro band of our large maternally-inherited ME RRF pedi gree are shown in fragm ent s comparably resolved . If this patient were heteroplasm ic for an int ragenic deletion, th en the PCR fragme nt encompassing th at region would appear as a doublet. Such a deletion could be further mapped by identifying double bands in the restriction fragments of that amplified region. In our MERR F patient, we observed no heteroplasmic int ragenic deletion. Th is was confirmed by de nsitometric analysis of the fragm ent mobility from the patient and by com paring the migration of his mtDNA fragm ent s with those of a control.
T his PCR experiment confirms our pre vious hypothesis that the mtDNA mutation of our MERRF pedigree (5) is a point mutation an d not a deletion. It also demonstrates the ut ility of thi s met hod for m apping intragenic m tDNA deletions.
Th is analysis ca n be exte nded to the nucleotide level by direct sequencing of asym metrically am plified PC R fragment s. By this procedure, the m tD NA seq uence can be rapidly screened for nucleotide substitutions as compared with available sequences 528 WALLACE ET AL. from a European white (27) and an American black (6) . A nucleotide substitution at ntl3702 found in the MERRF proband is shown in Figure 4 . This mutation changes a HaeIII restriction site, resulting in the fusion of two adjacent restriction fragments. In the lower right-hand panel of Figure 3 , the top band in lane 9 is the altered fragment that migrates more slowly on the gel than predicted from the published sequence. This nucleotide substitution was found in all the mtDNA of patients and controls, both black and white (6) , and is thus either a sequencing error or a common polymorphism.
During direct sequence analysis, nucleotide substitutions that alter amino acids become candidates for the disease-causing mutation. These can be tested to determine if they correlate with disease manifestations, either between pedigrees with the same symptoms, as for the homoplasmic mtDNA mutation of LHON, or between individuals in a pedigree, as for the heteroplasmic mtDNA mutation in MERRF. This screening is done using differential oligonucleotide hybridization to PCR-amplified mtDNA.
We observed an amino acid substitution in ATPase 6 that was a potential candidate for a MERRF mutation and which serves to illustrate the screening procedure. The nucleotide substitution is located at nt870 I. An A encodes a threonine (ACC), and a G encodes an alanine (GCC). The region surrounding this substitution was amplified using primers beginning at nt8557(~) and 8929(<-). The resulting 373-bp fragment was alkaline denatured, transferred to nylon membrane, and duplicate filters hybridized to 19-base oligonucleotide probes homologous to the two sequences (6) . Differential hybridization is shown in panels A and B of Figure 5 . This analysis revealed that the sequence found in MERRF was an amino acid polymorphism specific to Europeans, not found in Asians and Africans. Therefore, this mutation is not the cause of MERRF.
DISCUSSION
Current procedures for the diagnosis of neuromuscular diseases resulting from mtDNA mutations require substantial muscle biopsies; frequently, the biochemical and histologic diagnoses are ambiguous. The identification of specific mtDNA molecular defects responsible for these symptoms now permit accurate diagnosis. The ability to amplify mtDNA from small samples using PCR permits molecular diagnosis using much smaller specimens than previously possible. It is now apparent that, for a number of mtDNA encephalomyopathies, PCR will become the preferred procedure in the years to come.
Note added in proof Since this article was submitted, a mitochondrial point mutation at nt8334 (tRNALyS) has been demonstrated to cause MERRF (Shoffner 1M, Lott MT, Lezza AMS, Seibel P, Ballinger SW, Wallace DC 1990 Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial tRNALys mutation. Cell 61:931-937).
